Changes in TCR CDR3 Vβ profiles within CD45RA and CD45RO CD4 T cells and changes in TREC levels and the numbers of CD4 T-cell subpopulations after combination antiretroviral therapy. (A) Decrease in NPs within both CD45RA and CD45RO CD4 T cells from the baseline (BL), 2 to 6 months (M), and over 1 year (>1Y) posttherapy in patients P3, P4, P5, and P7. (B) Restoration of a Gaussian distribution of the TCR CDR3 length repertoire in Vβ3 and Vβ16 within CD45RA and CD45RO CD4 T-cell subsets from patients P7 at 2 months (2M) and 1 year (>1Y) after therapy. *, baseline oligoclonal expansions of 177- and 159-bp lengths within CD45RA and CD45RO T cells. (C) Change in log10 number of TREC copies/106 PBMCs (a) and changes in the number of naïve (b), EM (c), and CM (d) CD4 T cells (number of cells/μl) in three HIV-infected individuals (▴, patient P3; •, patient P5; ▪, patient P7) 48 weeks after therapy.